2004048575

19 AUG 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number
WO 03/074532 A1

(51) International Patent Classification[7]: C07D 495/04, 519/00, A61K 31/4709, A61P 3/00

(21) International Application Number: PCT/GB03/00877

(22) International Filing Date: 4 March 2003 (04.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0205165.4 6 March 2002 (06.03.2002) GB

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BIRCH, Alan, Martin** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **MORLEY, Andrew, David** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **STOCKER, Andrew** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **WHITTAMORE, Paul, Robert, Owen** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

[Continued on next page]

(54) Title: HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE



(1)

(57) Abstract: Heterocyclic amides of formula (1) wherein: X is N or CH; R^4 and R^5together are either -S-C(R^6)=C(R^7)- or -C(R^7)=C(R^6)-S-; R^6 and R^7 are independently selected from, for example hydrogen, halo and C_{1-4}alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R^1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R^2 is hydrogen, hydroxy or carboxy; R^3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C_{1-4}alkyl (optionally substituted by 1 or 2 R^8 groups); R^8 is selected from for example hydroxy, -COCOOR^9, -C(O)N(R^9)(R^{10}), -NHC(O)R^9, (R^9)(R^{10})N- and -COOR^9; R^9 and R^{10} are selected from for example hydrogen, hydroxy, C_{1-4}alkyl (optionally substituted by 1 or 2 R^{13}); R^{13} is selected from hydroxy, halo, trihalomethyl and C_{1-4}alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

WO 03/074532 A1



162162

ACTION